All In Biotech

Drug Trial Radar · NCT05266586

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Study to Evaluate the Effect of Obicetrapib 10 mg Daily in Combination With Ezetimibe 10 mg Daily as an Adjunct to High-Intensity Statin Therapy: The ROSE 2 Study

Last checked: Nov 19, 2026Latest source record: Jul 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 119 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

119

Actual

Start

Mar 9, 2022

Primary completion

Aug 12, 2022

Study completion Sep 8, 2022

Sponsor

Lead sponsor
NewAmsterdam PharmaIndustry
Sponsor type
Industry
First posted
Mar 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct to high-intensity statin therapy.

Conditions

  • Dyslipidemias
  • High Cholesterol
  • Hypercholesterolemia

Interventions

  • ObicetrapibDrug

    tablets

  • Ezetimibe 10mgDrug

    capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.

  • Obicetrapib placeboOther

    tablets; no active ingredient

  • Ezetimibe placeboOther

    capsules; no active ingredient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]Time frame: 12-weeks
  2. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]Time frame: 12-Weeks
  3. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]Time frame: 12-Weeks
  4. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]Time frame: 12-Weeks
  5. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]Time frame: 12-Weeks
  6. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]Time frame: 12-Weeks

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Velocity Clinical Research - Westlake d.b.a National Research Institute

    Los Angeles, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Ocala Cardiovascular Research

    Ocala, Florida

  • A & R Research Group, LLC

    Pembroke Pines, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • Meridian Clinical Research - Savannah, GA

    Savannah, Georgia

  • Velocity Clinical Research

    Meridian, Idaho

  • Biofortis, Inc

    Addison, Illinois

  • Northwest Heart Clinical Research, LLC

    Arlington Heights, Illinois

  • Midwest Institute for Clinical Research

    Indianapolis, Indiana

  • Research Integrity LLC

    Owensboro, Kentucky

  • Oakland Medical Research Center

    Troy, Michigan

  • Mercury Street Medical

    Butte, Montana

  • Meridian Clinical Research- Springdale, OH

    Cincinnati, Ohio

  • Aventiv Research, Inc.

    Columbus, Ohio

  • Summit Research Group, LLC

    Munroe Falls, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.